Mental illness affects millions of Americans, with anxiety disorders being the most common. According to the National Institute of Mental Health, an estimated 57.8 million adults in the U.S. live with some form of mental illness. Of these, approximately 42.5 million Americans struggle with anxiety disorders.
The company we are profiling today is Atai Life Sciences N.V. (ATAI), a clinical-stage biopharmaceutical company working towards addressing significant unmet patient needs in mental health disorders. Early this month, Atai announced a strategic merger with Beckley Psytech Limited, a private clinical-stage company advancing next-generation mental health therapies. The combined entity will operate under the name Atai Beckley, with the transaction expected to close in the second half of 2025.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.